ISDA

Deposition Date 2009-07-15

Release Date 2009-09-01

Last Version Date 2023-09-06

Entry Detail

PDB ID:

3IBE

Keywords:

TRANSFERASE

Title:

Crystal Structure of a Pyrazolopyrimidine Inhibitor Bound to PI3 Kinase Gamma

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Spodoptera frugiperda

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.80 Å

R-Value Free:

0.27

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform
Gene (Uniprot):PIK3CG
Chain IDs:A
Chain Length:966
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P48736 Pfam ID:PF00794, PF00792, PF00613, PF00454 EC:2.7.1.137

Ligand Molecules

L64

SO4

Primary Citation

ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines.

Zask, A, Verheijen, J.C, Curran, K, Kaplan, J, Richard, D.J, Nowak, P, Malwitz, D.J, Brooijmans, N, Bard, J, Svenson, K, Lucas, J, Toral-Barza, L, Zhang, W.G, Hollander, I, Gibbons, J.J, Abraham, R.T, Ayral-Kaloustian, S, Mansour, T.S, Yu, K.Show

J.Med.Chem. 52 5013 5016 (2009)

PMID: 19645448 DOI: 10.1021/jm900851f

Abstact

The mammalian target of rapamycin (mTOR), a central regulator of growth, survival, and metabolism, is a validated target for cancer therapy. Rapamycin and its analogues, allosteric inhibitors of mTOR, only partially inhibit one mTOR protein complex. ATP-competitive, global inhibitors of mTOR that have the potential for enhanced anticancer efficacy are described. Structural features leading to potency and selectivity were identified and refined leading to compounds with in vivo efficacy in tumor xenograft models.

Legend

Protein

Chemical

Disease

Primary Citation of related structures